Legal & General Group
VIR icon

Legal & General Group’s Vir Biotechnology VIR Stock Holding History

Legal & General Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.76M Buy
270,875
+14,126
+6% +$134K ﹤0.01% 1835
2026
Q1 		$2.3M Buy
256,749
+16,106
+7% +$128K ﹤0.01% 1860
2025
Q4 		$1.45M Sell
240,643
-4,328
-2% -$25.8K ﹤0.01% 2093
2025
Q3 		$1.4M Sell
244,971
-3,755
-2% -$19.2K ﹤0.01% 2129
2025
Q2 		$1.25M Buy
248,726
+13,876
+6% +$74.4K ﹤0.01% 2169
2025
Q1 		$1.52M Buy
234,850
+2,867
+1% +$25.5K ﹤0.01% 2022
2024
Q4 		$1.7M Sell
231,983
-13,821
-6% -$109K ﹤0.01% 2044
2024
Q3 		$1.84M Buy
245,804
+2,408
+1% +$20.9K ﹤0.01% 2014
2024
Q2 		$2.17M Sell
243,396
-7,893
-3% -$75.7K ﹤0.01% 1916
2024
Q1 		$2.55M Buy
251,289
+6,722
+3% +$68.5K ﹤0.01% 1827
2023
Q4 		$2.46M Buy
244,567
+902
+0.4% +$8.24K ﹤0.01% 1850
2023
Q3 		$2.28M Buy
243,665
+15,682
+7% +$224K ﹤0.01% 1839
2023
Q2 		$5.59M Buy
227,983
+5,781
+3% +$145K ﹤0.01% 1398
2023
Q1 		$5.17M Sell
222,202
-137
-0.1% -$3.5K ﹤0.01% 1397
2022
Q4 		$5.63M Buy
222,339
+3,901
+2% +$95.6K ﹤0.01% 1340
2022
Q3 		$4.21M Buy
218,438
+4,181
+2% +$106K ﹤0.01% 1440
2022
Q2 		$5.46M Buy
214,257
+158,982
+288% +$3.71M ﹤0.01% 1367
2022
Q1 		$1.42M Buy
55,275
+315
+0.6% +$9.34K ﹤0.01% 2112
2021
Q4 		$2.3M Buy
54,960
+1,026
+2% +$40.2K ﹤0.01% 1975
2021
Q3 		$2.35M Buy
53,934
+9,254
+21% +$401K ﹤0.01% 1949
2021
Q2 		$2.11M Buy
44,680
+16,371
+58% +$744K ﹤0.01% 1946
2021
Q1 		$1.45M Sell
28,309
-7,851
-22% -$423K ﹤0.01% 2100
2020
Q4 		$967K Buy
36,160
+8,875
+33% +$288K ﹤0.01% 2124
2020
Q3 		$937K Sell
27,285
-1,160
-4% -$49.9K ﹤0.01% 2046
2020
Q2 		$1.16M Buy
28,445
+27,316
+2,419% +$917K ﹤0.01% 1930
2020
Q1 		$39K Sell
1,129
-353
-24% -$9.49K ﹤0.01% 2682
2019
Q4 		$19K Buy
+1,482
New +$19.9K ﹤0.01% 3205

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Legal & General Group's VIR Position: Q2 2026 in Review

Legal & General Group increased its Vir Biotechnology (VIR) stake by 5.5% in Q2 2026, buying an estimated $134K and bringing the position to 270,875 shares worth $2.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1835.

Legal & General Group first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $5.63M in Q4 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Legal & General Group held 270,875 shares of Vir Biotechnology worth $2.76M as of Q2 2026.
  • Legal & General Group bought 14,126 Vir Biotechnology shares in Q2 2026, an estimated $134K.
  • Vir Biotechnology made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1835 holding.
  • Legal & General Group first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Legal & General Group's Vir Biotechnology position peaked at $5.63M in Q4 2022.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.